Dichloroacetate treatment accelerates the development of pathology in rodent autosomal recessive polycystic kidney disease

Vincent H. Gattone, Robert Bacallao

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Dichloroacetate (DCA) is a toxicant by-product from the chlorination disinfection process for municipal water. The levels would not affect people with normal renal and liver function. However, people with impaired renal or liver function may have an increased susceptibility to DCA toxicity as those are the organs affected by DCA. People (and rodents) with polycystic kidney disease (PKD) are polyuric, drink more fluids, and have both renal and liver pathology. In PKD, renal tubules and biliary epithelial cells proliferate to form cysts, which can eventually cause renal and/or liver dysfunction. Therefore, PKD may be a predisposing condition with an increased sensitivity to DCA toxicity. PCK rats are an orthologous model of human autosomal recessive PKD and were treated with 75 mg/l DCA in their drinking water. Male and female PCK and male Sprague-Dawley rats were treated from 4 to 8 wk of age, after which the severity of the renal and liver pathology induced by DCA were assessed. Only male PCK rats were adversely affected by DCA treatment, with an increase in the severity of renal cystic disease evinced by an increase in cystic enlargement and proteinuria. In conclusion, the chlorination byproduct DCA may adversely affect those with a preexisting renal disease, especially those who are polydipsic, like those with PKD.

Original languageEnglish
Pages (from-to)F1144-F1148
JournalAmerican Journal of Physiology - Renal Physiology
Volume307
Issue number10
DOIs
StatePublished - Nov 15 2014

Fingerprint

Autosomal Recessive Polycystic Kidney
Rodentia
Polycystic Kidney Diseases
Pathology
Kidney
Halogenation
Liver
Cystic Kidney Diseases
Preexisting Condition Coverage
Disinfection
Proteinuria
Drinking Water
Sprague Dawley Rats
Cysts
Liver Diseases
Epithelial Cells
Water

Keywords

  • Chlorination byproducts
  • Dichloroacetate
  • Polycystic kidney disease
  • Rat
  • Water

ASJC Scopus subject areas

  • Physiology
  • Urology
  • Medicine(all)

Cite this

Dichloroacetate treatment accelerates the development of pathology in rodent autosomal recessive polycystic kidney disease. / Gattone, Vincent H.; Bacallao, Robert.

In: American Journal of Physiology - Renal Physiology, Vol. 307, No. 10, 15.11.2014, p. F1144-F1148.

Research output: Contribution to journalArticle

@article{ad08159e627d4f0e9ff1d1c10d4207f3,
title = "Dichloroacetate treatment accelerates the development of pathology in rodent autosomal recessive polycystic kidney disease",
abstract = "Dichloroacetate (DCA) is a toxicant by-product from the chlorination disinfection process for municipal water. The levels would not affect people with normal renal and liver function. However, people with impaired renal or liver function may have an increased susceptibility to DCA toxicity as those are the organs affected by DCA. People (and rodents) with polycystic kidney disease (PKD) are polyuric, drink more fluids, and have both renal and liver pathology. In PKD, renal tubules and biliary epithelial cells proliferate to form cysts, which can eventually cause renal and/or liver dysfunction. Therefore, PKD may be a predisposing condition with an increased sensitivity to DCA toxicity. PCK rats are an orthologous model of human autosomal recessive PKD and were treated with 75 mg/l DCA in their drinking water. Male and female PCK and male Sprague-Dawley rats were treated from 4 to 8 wk of age, after which the severity of the renal and liver pathology induced by DCA were assessed. Only male PCK rats were adversely affected by DCA treatment, with an increase in the severity of renal cystic disease evinced by an increase in cystic enlargement and proteinuria. In conclusion, the chlorination byproduct DCA may adversely affect those with a preexisting renal disease, especially those who are polydipsic, like those with PKD.",
keywords = "Chlorination byproducts, Dichloroacetate, Polycystic kidney disease, Rat, Water",
author = "Gattone, {Vincent H.} and Robert Bacallao",
year = "2014",
month = "11",
day = "15",
doi = "10.1152/ajprenal.00009.2014",
language = "English",
volume = "307",
pages = "F1144--F1148",
journal = "American Journal of Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "10",

}

TY - JOUR

T1 - Dichloroacetate treatment accelerates the development of pathology in rodent autosomal recessive polycystic kidney disease

AU - Gattone, Vincent H.

AU - Bacallao, Robert

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Dichloroacetate (DCA) is a toxicant by-product from the chlorination disinfection process for municipal water. The levels would not affect people with normal renal and liver function. However, people with impaired renal or liver function may have an increased susceptibility to DCA toxicity as those are the organs affected by DCA. People (and rodents) with polycystic kidney disease (PKD) are polyuric, drink more fluids, and have both renal and liver pathology. In PKD, renal tubules and biliary epithelial cells proliferate to form cysts, which can eventually cause renal and/or liver dysfunction. Therefore, PKD may be a predisposing condition with an increased sensitivity to DCA toxicity. PCK rats are an orthologous model of human autosomal recessive PKD and were treated with 75 mg/l DCA in their drinking water. Male and female PCK and male Sprague-Dawley rats were treated from 4 to 8 wk of age, after which the severity of the renal and liver pathology induced by DCA were assessed. Only male PCK rats were adversely affected by DCA treatment, with an increase in the severity of renal cystic disease evinced by an increase in cystic enlargement and proteinuria. In conclusion, the chlorination byproduct DCA may adversely affect those with a preexisting renal disease, especially those who are polydipsic, like those with PKD.

AB - Dichloroacetate (DCA) is a toxicant by-product from the chlorination disinfection process for municipal water. The levels would not affect people with normal renal and liver function. However, people with impaired renal or liver function may have an increased susceptibility to DCA toxicity as those are the organs affected by DCA. People (and rodents) with polycystic kidney disease (PKD) are polyuric, drink more fluids, and have both renal and liver pathology. In PKD, renal tubules and biliary epithelial cells proliferate to form cysts, which can eventually cause renal and/or liver dysfunction. Therefore, PKD may be a predisposing condition with an increased sensitivity to DCA toxicity. PCK rats are an orthologous model of human autosomal recessive PKD and were treated with 75 mg/l DCA in their drinking water. Male and female PCK and male Sprague-Dawley rats were treated from 4 to 8 wk of age, after which the severity of the renal and liver pathology induced by DCA were assessed. Only male PCK rats were adversely affected by DCA treatment, with an increase in the severity of renal cystic disease evinced by an increase in cystic enlargement and proteinuria. In conclusion, the chlorination byproduct DCA may adversely affect those with a preexisting renal disease, especially those who are polydipsic, like those with PKD.

KW - Chlorination byproducts

KW - Dichloroacetate

KW - Polycystic kidney disease

KW - Rat

KW - Water

UR - http://www.scopus.com/inward/record.url?scp=84925182311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925182311&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00009.2014

DO - 10.1152/ajprenal.00009.2014

M3 - Article

C2 - 25234313

AN - SCOPUS:84925182311

VL - 307

SP - F1144-F1148

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1857

IS - 10

ER -